ClinicalTrials.gg
RecruitingNCT06952868Updated Aug 28, 2026

Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers

A Phase 2 interventional study of Drug: B10 L-BPA Injection in Head and Neck Cancer and Boron Neutron Capture Therapy, sponsored by China Medical University Hospital. Recruiting at 3 sites in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Head and Neck Neoplasms with a site in Taiwan — 24 open to participants now, 40 under way, 8 of them phase 3. Head and Neck Neoplasms · Taiwan.

Planned enrollment
83rd of 95
24 · median 110
Started
2025
with 7 others
Phase 2
25 of 118
3 open now
Primary completion
2026-08
later than 17 of 39 live
Registered
108th of 118
by date
Lead sponsor
4 of 118
China Medical University Hospital

Among the 118 studies in Head and Neck Neoplasms with a site in Taiwan, this one is the 83rd largest by planned enrollment of the 95 interventional ones that give a count, is one of 8 that started in 2025, is one of 25 in phase 2, reaches primary completion later than 17 of the 39 other live ones, and was the 108th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

24 of the 118 studies in Head and Neck Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Head and Neck Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

This Phase II study, titled "A Phase II Study to Evaluate the Efficacy and Safety of Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Patients with Unresectable Recurrent Head and Neck Cancers," aims to assess the efficacy and safety of B10 L-BPA-based BNCT in this patient population. The primary objective is to evaluate its efficacy, while secondary objectives include assessing safety, survival outcomes, tumor response, and the pharmacokinetics (PK) profile of B10 L-BPA and boron.

03

Conditions studied

  • Head and Neck Cancer
  • Boron Neutron Capture Therapy

Keywords

  • phase II
  • B10 L-BPA
  • BNCT
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject aged 18-80 (inclusive).
  2. or cytologically confirmed diagnosis of head and neck cancers with no distant in subjects as follows:

    1. Unresectable recurrent or persistent squamous cell carcinoma (SCC) after completing one of the following frontline therapies:

      • Standard concurrent chemoradiotherapy with a platinum-containing regimen.
      • Curative induction chemotherapy with a platinum-containing regimen, followed by radiation therapy.
      • Radiation therapy alone in the prior treatment for those who are unfit for a platinum-containing regimen or reject chemotherapy for the treatment of locoregional recurrence.
      • Concurrent chemoradiotherapy with a cetuximab-containing regimen in the prior treatment for those who are unfit for a platinum-containing regimen or reject other chemotherapy for the treatment of locoregional recurrence.
    2. Unresectable recurrent or persistent non-squamous cell carcinoma (nSCC) after receiving any type of frontline therapies.
  3. Subjects who are unsuitable for systemic therapies, or subjects who refuse systemic therapies.
  4. Receipt of prior radiation therapy between 40 Gray (Gy) and 75 Gy at the target lesion(s) for SCC patients and no more than 75 Gy at the target lesion(s) for nSCC patients.
  5. There must be a time interval ≥ 3 months between prior radiation therapy and the scheduled BNCT.
  6. There must be a time interval ≥ 1 month between receipt of antitumor drugs and the scheduled BNCT.
  7. by magnetic resonance imaging (MRI) and/or computed tomography (CT) scan and ≤ 7 cm in the longest dimension.
  8. At least one measurable lesion that can be assessed by version 1.1.
  9. (ECOG) Performance Score of 0-2.
  10. ≥ 3 months in the opinion of the investigator.
  11. Adequate organ functions as defined below:

    • ≥ 8.0 g/dL.
    • White blood cell (WBC) count ≥ 2.5 x 103/μL.
    • ≥ 1.5 × 103/μL.
    • count ≥ 80 × 103/μL.
    • (AST) ≤ 2.5 × (ULN).
    • Alanine aminotransferase (ALT) ≤ 2.5 × ULN.
    • Serum creatinine ≤ 1.5 × ULN.
  12. Negative serology test for (HIV) infection.
  13. Female subject with must have a negative result of serum pregnancy test at the screening visit and urine pregnancy test before the B10 L-BPA administration.
  14. Female subject with as well as male subject with reproductive potential must agree to refrain from unprotected sex and use 2 methods of highly effective with their partner (e.g. barrier contraceptives [male condom, female condom, or diaphragm plus spermicide], intrauterine device, hormonal methods [hormone shot or injection, implants, combination oral contraceptives, or patches]) until the end of this study.
  15. Physically and mentally capable of participating in the study and willing to adhere to study procedures.
  16. Provision of signed .

Exclusion criteria

Exclusion Criteria:

  1. Presence of secondary cancer with the exception of carcinoma in situ and skin cancers after curative surgery.
  2. Synchronous multiple head and neck cancers outside the field of neutron beam irradiation.
  3. Distant outside of the head and neck region.
  4. Imaging studies, e.g., CT, MRI, demonstrating tumor invasion into the carotid artery.
  5. Unsuitable for the BNCT, as assessed by the investigator based on the investigator-determined computed tomography angiography (CTA) of head and neck in suspected cases of tumor invasion into the carotid artery.
  6. Presence of any ≥ Grade 3 toxicity (e.g., mucositis, stomatitis, and skin inflammation) at the prior irradiation area, as assessed by the version 5.0.
  7. Presence of ≥ Grade 3 cataract, as assessed by the NCI-CTCAE version 5.0.
  8. Active infections requiring systemic treatment within 2 weeks of the screening visit.
  9. Myocardial infarction, unstable angina, or poorly controlled arrhythmia within 6 months prior to the scheduled BNCT.
  10. Severe comorbidities including but not limited to poorly controlled epilepsy, poorly controlled diabetes mellitus, poorly controlled hypertension, chronic lung diseases, e.g., obstructive pneumonia, interstitial pneumonia, pulmonary fibrosis, and severe emphysema, kidney diseases, e.g., chronic renal failure, acute renal failure, and nephrotic syndrome, cardiac diseases, e.g., (NYHA) Functional Classification Class III or IV, and/or other severe conditions in the opinion of the investigator.
  11. Suspected or known (including allergy) to any of B10 L-BPA components (e.g., L-phenylalanine) or contrast media.
  12. History of prior BNCT.
  13. Subject with hereditary fructose intolerance.
  14. Subject with phenylketonuria.
  15. Presence of any dental conditions necessitating tooth extraction within 2 weeks before and after the BNCT, as assessed by the dentist.
  16. Restless subjects who were unable to lie or sit in a cast for more than 30 minutes.
  17. Any medical or psychiatric conditions that, in the opinion of the investigator, may interfere with optimal participation in the study or place the subject at increased risk of adverse events (AEs).
  18. Received any drug or device or have participated in a clinical study within 4 weeks prior to the screening visit.
  19. History of substance or alcohol abuse within 6 months prior to the screening visit.
  20. Female subject who is planning to be pregnant or lactating during the study period.
  21. Subject who is considered unfit to participate in the clinical study as assessed by the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Single arm treated by BNCT only

    Drug: Drug: B10 L-BPA Injection

Interventions

  • DrugDrug: B10 L-BPA Injection

    The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron. This single arm of the study is designed to evaluate the therapeutic efficacy of BNCT, wherein patients receive B10 L-BPA administration followed by neutron irradiation.

06

What researchers measure

Primary outcomes

  1. Assessment of the Efficacy of B10 L-BPA-Based BNCT in Unresectable Recurrent Head and Neck Cancers

    The objective response rate (ORR) of the B10 L-BPA-based BNCT, as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. ORR is defined as the proportion of subjects whose best overall response is either complete response (CR) or partial response (PR) of the target lesions.

    Time frame: 6 months

Secondary outcomes

  1. Evaluation of the Safety of B10 L-BPA-Based BNCT in Unresectable Recurrent Head and Neck Cancers

    Safety parameters, including occurrence, severity, and relationship of the treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs), as assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 during the study period.

    Time frame: 6 months

  2. Assessment of the Survival Status of B10 L-BPA-Based BNCT in Unresectable Recurrent Head and Neck Cancers

    PFS is defined as the time from receiving the B10 L-BPA-based BNCT until progressive disease (PD) or death from any cause, whichever comes the first. OS is defined as the time from receiving the B10 L-BPA-based BNCT until death from any cause.

    Time frame: 6 months

  3. Assessment of Tumor Responses to B10 L-BPA-Based BNCT in Unresectable Recurrent Head and Neck Cancers

    Tumor responses, including complete response (CR), partial response (PR), stable disease (SD), objective response rate (ORR), disease control rate (DCR), duration of response (DoR), time to CR, and time to PR, as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: 6 months

  4. Peak Plasma Concentration (Cmax)

    Maximum observed concentration of B10 L-BPA in plasma.

    Time frame: 3 Days

  5. Time to Peak Plasma Concentration (Tmax)

    Time at which the maximum observed plasma concentration (Cmax) of B10 L-BPA occurs.

    Time frame: 3 Days

  6. Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration-time curve from time 0 to the last measurable concentration of B10 L-BPA.

    Time frame: 3 Days

  7. Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity for B10 L-BPA.

    Time frame: 3 Days

  8. Elimination Half-Life (t1/2)

    Time required for the plasma concentration of B10 L-BPA to decrease by half.

    Time frame: 3 Days

  9. Percentage of Recovered B10 L-BPA in Urine

    Percentage of the administered B10 L-BPA dose recovered in urine.

    Time frame: 3 Days

  10. Percentage of Recovered B10 L-BPA Metabolites in Urine

    Percentage of the administered B10 L-BPA metabolites recovered in urine.

    Time frame: 3 Days

  11. Renal Clearance of B10 L-BPA

    Renal clearance rate of B10 L-BPA based on urine and plasma concentrations.

    Time frame: 3 Days

Other outcomes

  1. Assessment of the Population of Circulating Immune Cells and Associated Cytokines Before and After B10 L-BPA-Based BNCT

    Blood samples will be collected to assess MDSCs, T cells and interleukin-1 β at multiple time points: before and after BNCT. This approach aims to clarify whether the levels of circulating immune cells could serve as prognostic indicators for BNCT treatment outcomes.

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2026, 15 months after the start.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 15 months is below that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
May 1, 2025
StartActual
May 23, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06952868
Collaborators
Heron Neutron Medical Corp.
Responsible party
Sponsor
First posted
May 1, 2025
Start date
May 23, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion